Phil Deschamps | Chief Executive Officer |
Joyce LaViscount | Chief Financial Officer & Chief Operating Officer |
Ryan Scott | Clinic Director at Advantage 4 Athletes |
Steven Lichtman | Oppenheimer & Company |
Jeff Porter | Porter Capital |
Anthony Lamport | Lambda Fund |
Good morning, ladies and gentlemen, and welcome to the Third Quarter of Fiscal Year 2019 Earnings Conference Call for Helius Medical Technologies. At this time, all participants have been placed in a listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the company’s website for replay shortly.
Before we began, I'd like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management, including statements regarding the potential FDA marketing authorization of the PoNS device, the success of the company's planned study, the future commercialization of the PoNS treatment, expected future clinical and regulatory time lines, the potential receipt of regulatory clearance of the PoNS device in the United States and projected financial results. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including those identified in the Risk Factors section in our most recent annual report on Form 10-K filed with the SEC on March 14, 2019 and as well as those in the Form 10-Q for the third quarter ended September 30, 2019, which was filed with the SEC this morning.